Company profile: DTx Pharma
1.1 - Company Overview
Company description
- Provider of RNA-based therapeutic technologies aimed at treating genetic drivers of disease. Develops delivery approaches to enable personalized treatment across therapeutic areas, addressing limitations of earlier platforms such as poor pharmacokinetics and insufficient cellular uptake.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to DTx Pharma
Rocket Pharmaceuticals
HQ: United States
Website
- Description: Provider of gene therapies for rare childhood disorders, developing lentiviral and AAV vector-based programs including RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, an AAV program for Danon Disease, and gene therapies for LAD-I, PKP2 arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rocket Pharmaceuticals company profile →
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
Akamis Bio
HQ: United Kingdom
Website
- Description: Provider of clinical-stage oncology therapeutics using its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to develop viral vector-based gene therapies that target solid tumors and express therapeutic proteins to stimulate an immune response. Offerings include NG-350A (secreted CD40 agonist monoclonal antibody expressed within tumors), clinical trials of T-SIGn® agents, and collaborations with academia, research institutes, and biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akamis Bio company profile →
Mirus Bio
HQ: United States
Website
- Description: Provider of nucleic acid-based technologies and gene transfer methods for the pharmaceutical business, including a proprietary RNAi delivery platform and tools for gene expression and biotherapeutic protein. Products include TransIT-VirusGEN for AAV/lentivirus vector production in research and clinical applications, RevIT AAV Enhancer, TransIT-LT1 transfection reagent, and GMP-grade ancillary materials for cell and gene therapy manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirus Bio company profile →
Voyager Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy and neurology-focused biotechnology solutions, offering the TRACER AAV capsid discovery platform for BBB-crossing capsids and a pipeline including anti-tau antibody (VY-TAU01), SOD1 silencing gene therapy (VY9323) for ALS, tau and anti-Aβ gene therapies for Alzheimer’s, and FXN gene therapy for Friedreich’s Ataxia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Voyager Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for DTx Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to DTx Pharma
2.2 - Growth funds investing in similar companies to DTx Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for DTx Pharma
4.2 - Public trading comparable groups for DTx Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →